A Phase 2 to Evaluate the Dose-Response Relationship and Safety of JTT-751 in Patients with Iron Deficiency Anemia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223256

Enrollment

120

Registered

2016-07-06

Start date

2016-07-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia

Interventions

investigational material(s) Generic name etc : Ferric Citrate Hydrate INN of investigational material : - Therapeutic category code : 322 Mineral preparations Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Iron deficiency anemia Hemoglobin level of= > 7.0 g/dL and < 11.0 g/dL

Exclusion criteria

Exclusion criteria: Anemia caused by other than iron deficiency Serum phosphate < 2.5 mg/dL Uncontrollable treatment potentially affecting bleeding in patients with bleeding lesion

Design outcomes

Primary

Measure	Time frame
efficacy Changes in hemoglobin level	—

Secondary

Measure	Time frame
efficacy Changes in erythrocyte- and iron-related test values	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026